A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
43
30mg for 48 weeks
10mg for 48 weeks
Seoul National University Bundang Hospital
Bundang, South Korea
Seoul National University Hospital
Seoul, South Korea
Proportion of patients with HBV DNA below 300copies/mL
Time frame: at week 48
The change of HBV DNA from the baseline
Time frame: at week 24, 48
Proportion of patients with HBV DNA below LOD of RT-PCR
Time frame: at week 24, 48
ALT normalization rate
Time frame: at week 24, 48
Proportion of patients with viral breakthrough during 48-week treatment period
Time frame: at week 24, 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.